2023 World Conference on Lung Cancer (Posters)-EP12.01. Real-word Study of Aumolertinib Treatment for Advanced NSCLC Patients with Uncommon EGFR Mutations in Late Permian Coal Area

EP12.01. Real-word Study of Aumolertinib Treatment for Advanced NSCLC Patients with Uncommon EGFR Mutations in Late Permian Coal Area - PDF(Slides)

Back to course

Pdf Summary

This document provides an overview of a real-world study conducted in the late Permian coal-accumulating area in China to evaluate the efficacy and safety of aumolertinib in the treatment of advanced non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations. The study aims to address the high unmet need for treatment in this specific region, known for its high incidence and mortality rate of lung cancer.<br /><br />Aumolertinib, a third-generation EGFR-TKI, has previously shown effectiveness in tumors with EGFR mutations and T790M resistance mutation. The study plans to assess the drug's efficacy and safety as a first-line treatment for NSCLC patients with uncommon EGFR mutations in the coal-accumulating areas. The study will also utilize peripheral blood for dynamic monitoring and analyze tissue and peripheral blood to understand drug resistance mechanisms.<br /><br />The study design is a single-arm, prospective, multicenter, real-world clinical trial. The key inclusion criteria for patient selection include being 18 years or older, having locally advanced or metastatic NSCLC, harboring uncommon mutations confirmed by tissue or blood tests, and having no prior first-line systemic therapy. Patients with asymptomatic CNS metastases and at least one non-irradiated measurable lesion are allowed. The primary endpoint of the study is the objective response rate (ORR), while secondary endpoints include disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety.<br /><br />The document also emphasizes that the study is currently enrolling participants and provides a link for more information about the study.<br /><br />In summary, this study aims to evaluate the efficacy and safety of aumolertinib as a first-line treatment for NSCLC patients with uncommon EGFR mutations in the coal-accumulating areas of China. The study design is a single-arm, prospective, multicenter, real-world clinical trial, and the primary endpoint is the objective response rate. The study is currently ongoing and enrolling participants.

Asset Subtitle

Jia gang Feng

Meta Tag

Speaker Jia gang Feng

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

real-world study

late Permian coal-accumulating area

China

aumolertinib

advanced non-small cell lung cancer

NSCLC

uncommon EGFR mutations

efficacy and safety

high incidence

mortality rate